BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC
As a result, the repaired tendon remains more susceptible to reinjury even after the remodeling phase is complete
Before the infusion begins, a brief health screening confirms candidacy, reviews current medications and any contraindications, and identifies customization preferences such as additional wellness boosters or adjusted dosages
People take it to increase stamina, burn fat during workouts, and speed up their metabolism